Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site.
P Usharani, … , C K Kasper, S P Bajaj
P Usharani, … , C K Kasper, S P Bajaj
Published January 1, 1985
Citation Information: J Clin Invest. 1985;75(1):76-83. https://doi.org/10.1172/JCI111700.
View: Text | PDF
Research Article Article has an altmetric score of 3

Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site.

  • Text
  • PDF
Abstract

Abnormal factor IX variant proteins were isolated from the plasmas of three unrelated severe hemophilia-B families that had been previously shown to contain functionally impaired molecules immunologically similar to normal factor IX. The families studied were: (1) a patient with markedly prolonged ox brain prothrombin time, designated factor IX Bm Lake Elsinore (IXBmLE); (b) three patients (brothers) with moderately prolonged ox brain prothrombin time, designated factor IX Long Beach (IXLB); and (c) a patient with normal ox brain prothrombin time designated factor IX Los Angeles (IXLA). Each variant molecule comigrates with normal factor IX (IXN) both in the sodium dodecyl sulfate and in the nondenaturing alkaline gel electrophoresis. All three variant proteins are indistinguishable from IXN in their amino acid compositions, isoelectric points, carbohydrate distributions and number of gamma-carboxyglutamic acid residues. Each variant protein undergoes a similar pattern of cleavage by factor XIa/Ca2+ and by factor VIIa/Ca2+/tissue factor, and is activated at a rate similar to that observed for IXN. All of the three variant proteins also react with an anti-IXN monoclonal antibody that interferes with the binding of activated IXN(IXaN) to thrombin-treated factor VIIIC. However, in contrast to IXaN, the cleaved IXBmLE has negligible activity (approximately 0.2%), and cleaved forms of IXLA and IXLB have significantly reduced activity (approximately 5-6%) in binding to antithrombin-III/heparin, and in activating factor VII (plus Ca2+ and phospholipid) or factor X (plus Ca2+ and phospholipid) +/- factor VIII. These data, taken together, strongly indicate that the defect in these three variant proteins resides near or within the latent catalytic site. This results in virtually a complete loss of catalytic activity of the cleaved IXBmLE molecule and approximately 95% loss of catalytic activity of the cleaved IXLA and IXLB molecules.

Authors

P Usharani, B J Warn-Cramer, C K Kasper, S P Bajaj

×

Total citations by year

Year: 2022 2021 2012 2010 2000 1999 1996 1995 1994 1993 1991 1990 1989 1988 1987 1986 1985 Total
Citations: 1 2 1 1 1 1 1 1 1 2 2 2 2 1 1 2 2 24
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (24)

Title and authors Publication Year
The Molecular Basis of FIX Deficiency in Hemophilia B.
Shen G, Gao M, Cao Q, Li W
International journal of molecular sciences 2022
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes
A Branchini, M Morfini, B Lunghi, D Belvini, P Radossi, L Bury, ML Serino, P Giordano, D Cultrera, AC Molinari, M Napolitano, E Bigagli, G Castaman, M Pinotti, F Bernardi, P Agostini, C Biasioli, TM Caimi, F Daniele, A Dragani, D Gemmati, P Gresele, S Linari, G Rossetti, C Santoro, R Santoro, G Sottilotta, J Svahn
Journal of Thrombosis and Haemostasis 2021
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.
Branchini A, Morfini M, Lunghi B, Belvini D, Radossi P, Bury L, Serino ML, Giordano P, Cultrera D, Molinari AC, Napolitano M, Bigagli E, Castaman G, Pinotti M, Bernardi F
Journal of Thrombosis and Haemostasis 2021
Methods in Enzymology
JD Stone, AS Chervin, DH Aggen, DM Kranz
Protein Engineering for Therapeutics Part B 2012
Vitamins & Hormones
KJ Hare, FK Knop
Vitamins & Hormones 2010
Detailed characterization of an anti-factor IX monoclonal antibody that neutralizes the prolonged ox brain prothrombin time of hemophilia BM by synthetic peptides
I Takahashi, T Kojima, M Sano, T Watanabe, T Kamiya, H Saito
Peptides 2000
Protease and EGF1 Domains of Factor IXa Play Distinct Roles in Binding to Factor VIIIa: IMPORTANCE OF HELIX 330 (HELIX 162 IN CHYMOTRYPSIN) OF PROTEASE DOMAIN OF FACTOR IXa IN ITS INTERACTION WITH FACTOR VIIIa
A Mathur, SP Bajaj
The Journal of biological chemistry 1999
Anticoagulant repertoire of the hookworm Ancylostoma caninum
P Stassens, PW Bergum, Y Gansemans, L Jespers, Y Laroche, S Huang, S Maki, J Messens, M Lauwereys, M Cappello, PJ Hotez, I Lasters, GP Vlasuk
Proceedings of the National Academy of Sciences 1996
Evidence Suggestive of Activation of the Intrinsic Pathway of Blood Coagulation After Injection of Factor Xa/Phospholipid Into Rabbits
BJ Warn-Cramer, SI Rapaport
Arteriosclerosis, thrombosis, and vascular biology 1995
Prothrombin time using thromboplastins of different origin in hemophilia BM patients
A Girolami, E Zanon, P Radossi, S Gavasso
American Journal of Hematology 1994
Comparison of the behavior of normal factor IX and the factor IX BM variant hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources
JB Lefkowitz, DM Monroe, CK Kasper, HR Roberts
American Journal of Hematology 1993
Mutations in the catalytic domain of factor IX that are related to the subclass hemophilia Bm
N Hamaguchi, H Roberts, DW Stafford
Biochemistry 1993
Identification of a new haemophilia BMcase produced by a mutation located at the carboxy terminal cleavage site of activation peptide
J Solera, M Magallón, J Martin-Villar, A Coloma
British Journal of Haematology 1991
A sulfated rabbit endothelial cell glycoprotein that inhibits factor VIIa/tissue factor is functionally and immunologically identical to rabbit extrinsic pathway inhibitor (EPI)
BJ Warn-Cramer, SL Maki, SI Rapaport
Thrombosis Research 1991
Replacement of isoleucine-397 by threonine in the clotting proteinase factor IXa (Los Angeles and Long Beach variants) affects macromolecular catalysis but not L-tosylarginine methyl ester hydrolysis. Lack of correlation between the ox brain prothrombin time and the mutation site in the variant proteins
SG Spitzer, BJ Warn-Cramer, CK Kasper, SP Bajaj
Biochemical Journal 1990
Experimental and theoretical evidence supporting the role of Gly363 in blood coagulation factor IXa (Gly193 in chymotrypsin) for proper activation of the proenzyme
SP Bajaj, SG Spitzer, WJ Welsh, BJ Warn-Cramer, CK Kasper, JJ Birktoft
The Journal of biological chemistry 1990
Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Troed-y-Rhiw
MB Liddell, DP Lillicrap, IR Peake, AL Bloom
British Journal of Haematology 1989
Blood clotting factor IX BM Nagoya
K Suehiro, S Kawabata, T Miyata, H Takeya, J Takamatsu, K Ogata, T Kamiya, H Saito, Y Niho, S Iwanaga
The Journal of biological chemistry 1989
Molecular defect in factor IXBm Lake Elsinore. Substitution of Ala390 by Val in the catalytic domain
SG Spitzer, UR Pendurthi, CK Kasper, SP Bajaj
The Journal of biological chemistry 1988
Partial purification and characterization of extrinsic pathway inhibitor (the factor xa-dependent plasma inhibitor of factor VIIa/tissue factor)
BJ Warn-Cramei, SL Maki, A Zivelin, SI Rapaport
Thrombosis Research 1987
Intrinsic versus extrinsic coagulation. Kinetic considerations
BJ Warn-Cramer, SP Bajaj
Biochemical Journal 1986
Heterogeneity of factor IX BM difference of cleavage sites by factor XIa and Ca2+in factor IX Kashihara, Factor IX Nagoya and Factor IX Niigata
A Yoshioka, Y Ohkubo, T Nishimura, I Tanaka, H FuKui, K Ogata, T Kamiya, H Takahashi
Thrombosis Research 1986
The characterization of a panel of monoclonal antibodies to human coagulation factor IX
H Bessos, LR Micklem, M McCann, K James, D Brian, L McClelland, CV Prowse
Thrombosis Research 1985
Structure and Function of Factor IX: Defects in Haemophilia B
RA Mccgraw, LM Davis, RL Lundblad, DW Stafford, HR Roberts
Clinics in Haematology 1985

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 3 patents
6 readers on Mendeley
See more details